{"organizations": [], "uuid": "940cbb16c7577751aee42a3c1bb10532820681db", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cara-therapeutics-initiates-pivota/brief-cara-therapeutics-initiates-pivotal-phase-3-efficacy-trial-of-korsuva-injection-idUSASB0C36Y", "country": "US", "domain_rank": 408, "title": "BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T14:04:00.000+02:00", "replies_count": 0, "uuid": "940cbb16c7577751aee42a3c1bb10532820681db"}, "author": "", "url": "https://www.reuters.com/article/brief-cara-therapeutics-initiates-pivota/brief-cara-therapeutics-initiates-pivotal-phase-3-efficacy-trial-of-korsuva-injection-idUSASB0C36Y", "ord_in_thread": 0, "title": "BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "efficac", "sentiment": "negative"}, {"name": "brief-cara therapeutics initiates pivotal phase", "sentiment": "negative"}, {"name": "trial of korsuva injection reuters", "sentiment": "none"}, {"name": "cara therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 31, 2018 / 12:04 PM / in 9 minutes BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection Reuters Staff 1 Min Read \nJan 31 (Reuters) - Cara Therapeutics Inc: \n* CARA THERAPEUTICS INITIATES PIVOTAL PHASE 3 EFFICACY TRIAL OF KORSUVAâ„¢ (CR845/DIFELIKEFALIN) INJECTION IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-31T14:04:00.000+02:00", "crawled": "2018-01-31T14:16:04.000+02:00", "highlightTitle": ""}